Edition:
United States

Medical Equipment, Supplies & Distribution

Page 1

KKR Fund Holdings LP reports 5.5 pct stake in Entellus Medical

Friday, 21 Jul 2017 05:05pm EDT

July 21 (Reuters) - Entellus Medical Inc :KKR Fund Holdings LP reports 5.5 percent stake in Entellus Medical Inc as of July 13 - SEC filing.

Tearlab announces European regulatory clearance for Tearlab Discovery System

Friday, 21 Jul 2017 07:00am EDT

July 21 (Reuters) - Tearlab Corp :Tearlab announces European regulatory clearance for next-generation Tearlab Discovery System.

Ypsomed to separate from Insulet

Friday, 21 Jul 2017 01:12am EDT

July 21 (Reuters) - YPSOMED HOLDING AG ::TO SEPARATE FROM INSULET AND EXTEND ITS PORTFOLIO WITH AN OWN PATCH PUMP IN MID-TERM.AFTER 30 JUNE 2018, INSULET CORP. WILL TAKE OVER OMNIPOD BUSINESS WORLDWIDE.DETAILS OF TRANSFER PROCESS ARE PRESENTLY BEING WORKED OUT BETWEEN TWO PARTIES.‍DISTRIBUTION AGREEMENT WITH INSULET CORP. WILL END AS PER 30 JUNE 2018​.‍PARTIES COULD NOT AGREE ON EXTENDING CONTRACT AS PRICE DEMANDED BY INSULET CORP. WOULD HAVE MADE CONTINUED ECONOMIC VIABILITY IMPOSSIBLE​.IN FUTURE, YPSOMED WILL FOCUS ON ITS OWN DEVELOPMENTS.IS TO RECEIVE SOME USD 50 MILLION IN COMPENSATION FROM INSULET CORP. TO SET UP EUROPEAN DISTRIBUTION STRUCTURES FOR MYLIFE OMNIPOD.

Sartorius Stedim Biotech 2017 first-half figures

Friday, 21 Jul 2017 01:01am EDT

July 21 (Reuters) - SARTORIUS STEDIM BIOTECH SA ::SARTORIUS STEDIM BIOTECH S.A.: 2017 FIRST-HALF FIGURES.H1 SALES EUR 546.7 MILLION VERSUS EUR 508.8 MILLION YEAR AGO.H1 EBITDA EUR 2) 147.4 MILLION VERSUS EUR 136.4 MILLION YEAR AGO.H1 NET PROFIT EUR 89.7 MILLION VERSUS EUR 83.5 MILLION YEAR AGO.SSB CONTINUES TO PROJECT CAPITAL EXPENDITURES OF AROUND 10% TO 13% OF SALES IN CURRENT YEAR..CONFIRMED ITS FULL-YEAR FORECAST FOR 2017.PROJECTS SALES REVENUE TO INCREASE BY ABOUT 8% TO 12%.PROJECTS UNDERLYING EBITDA MARGIN TO RISE BY APPROX. 0.5 PERCENTAGE POINTS OVER PRIOR-YEAR FIGURE OF 27.5%.BOTH FORECASTS GIVEN IN CONSTANT CURRENCIES.

Insulet to assume distribution and commercial support for its Omnipod system in Europe

Thursday, 20 Jul 2017 04:01pm EDT

July 20 (Reuters) - Insulet Corp :Insulet to assume distribution and commercial support for its Omnipod system in Europe.Insulet Corp says does not expect this change to have a material impact on its previously provided 2017 financial guidance.Insulet - excluding any one-time costs, once direct European operations are established, anticipates it will be accretive to earnings.

TSO3 files for an extended claim for duodenoscopes

Thursday, 20 Jul 2017 10:45am EDT

July 20 (Reuters) - TSO3 Inc ::TSO3 files for an extended claim for duodenoscopes.Has filed a 510(k) submission with US regulators for its STERIZONE VP4 Sterilizer.Filing supported by lab data validating STERIZONE VP4 Sterilizer can terminally sterilize multi-channel flexible endoscopes with a duodenovideoscope.

NeuroMetrix reports Q2 2017 financial results

Thursday, 20 Jul 2017 07:00am EDT

July 20 (Reuters) - Neurometrix Inc :Q2 revenue rose 63 percent to $4.3 million.NeuroMetrix Inc - loss from operations was $3.4 million in Q2 2017 versus $4.2 million in Q2 2016.

Biomerieux H1 sales up at 1,134 million euros

Thursday, 20 Jul 2017 01:10am EDT

July 20 (Reuters) - BIOMERIEUX SA ::SALES UP 11.3% OVER FIRST HALF AT CONSTANT EXCHANGE RATES AND SCOPE OF CONSOLIDATION​.H1 €1,134 MILLION IN SALES‍​.‍FOR 2017 CONFIDENT THAT IT WILL ACHIEVE HIGHER END OF ITS TARGET ORGANIC SALES GROWTH RANGE OF BETWEEN 8% AND 9%​.

Ansell announces $100 mln restructuring after condom biz sale

Wednesday, 19 Jul 2017 07:02pm EDT

July 20 (Reuters) - Ansell Ltd ::Will implement a four-point transformation program following a review of business portfolio and agreed divestment of sexual wellness business.Will make a cash investment over a three-year period of US$70-$100m as part of a significant business transformation.Investment with an additional US$20-30m in non-cash asset write-downs.About US$40-50m of above cash investment will enable a cost reduction program.Program expected to deliver annualized pre-tax savings in excess of US$30m by f'20, with savings of about US$5-7m to be realized in f'18..Additional non-cash asset write-downs are expected to arise primarily on closure of smaller, less efficient production lines.Provisional unaudited f'17 divested EBIT of sexual wellness GBU is US$40m with profit attributable of US$28m.Continues to anticipate gross proceeds from divestment of US$600m.Net proceeds from divestment estimated at $529m after deducting estimated tax and transaction costs..Retained net proceeds not redeployed in further acquisitions or on share buyback expected to reduce net interest expense at a marginal rate of 2.1 to 2.3pct.

Ekso Bionics announces proposed $34 million rights offering

Wednesday, 19 Jul 2017 09:05am EDT

July 19 (Reuters) - Ekso Bionics Holdings Inc :Ekso Bionics announces proposed $34 million rights offering; committed investment from Puissance Capital Management to support rights offering.Ekso Bionics Holdings Inc - ‍Board of directors has approved a proposed rights offering to raise gross proceeds of up to $34 million ​.Ekso - intends to use net proceeds from proposed rights offering to accelerate adoption of ekso in rehabilitation market.Ekso Bionics Holdings Inc - rights offering of up to 34 million shares of company's common stock at a subscription price of $1.00 per share.

Markets

  • Sectors
  • U.S.
  • Europe
  • Asia

Sector Summary